11 research outputs found
Rationale and design of the enoximone clinical trials program.
No full text17nonenoneLOWES BD; SHAKAR SF; METRA M; FELDMAN AM; EICHHORN E; FREYTAG JW; GERBER MJ; LIARD JF; HARTMAN C; GORCZYNSKI R; EVANS G; LINSEMAN JV; STEWART J; ROBERTSON AD; ROECKER EB; DEMETS DL; BRISTOW MRLowes, Bd; Shakar, Sf; Metra, Marco; Feldman, Am; Eichhorn, E; Freytag, Jw; Gerber, Mj; Liard, Jf; Hartman, C; Gorczynski, R; Evans, G; Linseman, Jv; Stewart, J; Robertson, Ad; Roecker, Eb; Demets, Dl; Bristow, M
Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial.
No full textThe initial slope of the VCO2/VO2-curve (s1) in cardiopulmonary exercise testing is a strong and independent predictor of outcome in patients with previous myocardial infarction
No full text
Usefulness of combining admission brain natriuretic peptide (BNP) plus hospital discharge bioelectrical impedance vector analysis (BIVA) in predicting 90Â days cardiovascular mortality in patients with acute heart failure
No full textLow-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving β-blocking agents
No full text
Modulation of β-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5
No full text
